Research Institute of the MUHC Focused on COVID-19 Priorities
Montreal, April 8, 2020—The Board of Directors of the Research Institute of the McGill University Health Centre (RI-MUHC) acknowledged today Dr. Constantine Stratakis’ decision to withdraw from his RI-MUHC and associated appointments at the MUHC and McGill University. Dr. Stratakis, who was scheduled to take up his responsibilities on June 1, 2020, confirmed that circumstances beyond his and his family's control forced him to reconsider their future. The Board will be meeting to discuss the next steps to staff the position of Executive Director and Chief Scientific Officer (ED/CSO). As Interim ED/CSO, Dr. Bruce Mazer will continue to assure the leadership of the RI-MUHC at this time. Given the essential-work-only directives from Government during the COVID-19 pandemic, the RI-MUHC is focused predominantly on the numerous clinical trials to understand the coronavirus that are being led by its investigators, as well as on their tireless efforts to develop a vaccine and other related innovations.
About the Research Institute of the MUHC
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 420 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Québec – Santé (FRQS). www.rimuhc.ca
